Clinical Trial Data Fraud in South Florida: What Research Sites Need to Know

The FDA's criminal arm just charged another South Florida research center with faking clinical trial data, and the pattern is no longer subtle. A federal grand jury in the Southern District of Florida indicted the principal investigator and staff at a Pembroke Pines research site, alleging they fabricated test results and invented patient participation in trials for drugs awaiting FDA approval. If you own a research site, serve as a principal investigator, or work as a clinical research coordinator in Florida, this case is a warning you should not read past.

FDA's Office of Criminal Investigations and DOJ's Health and Safety Unit have charged clinical trial data fraud as wire fraud conspiracy in the Southern District of Florida. The prior cases have produced real custodial sentences.

Key Takeaways

• The FDA's Office of Criminal Investigations and DOJ's Health and Safety Unit charge clinical trial data fraud as conspiracy and wire fraud under 18 U.S.C. §§ 1349 and 1343.
• Each wire fraud count carries a statutory maximum of 20 years in prison, and these are routinely multi-count indictments that stack exposure quickly.
• South Florida is the most active clinical trial fraud enforcement zone in the country, with repeat prosecutions out of Miami and Broward research sites.
• Principal investigators, site owners, and study coordinators have all gone to federal prison in prior Southern District of Florida cases, with sentences from 30 to 71 months.
• These cases are built quietly through FDA inspections and sponsor records long before charges, so pre-indictment defense is where the outcome is actually decided.

What Actually Happened

On June 10, 2026, the Justice Department announced that a federal grand jury in the Southern District of Florida had returned an indictment against a medical doctor and two staff members at a Pembroke Pines research center, with a third staff member charged separately by criminal information. The government alleges that, beginning no later than 2019, the group fabricated testing data and falsified records during clinical trials sponsored by a pharmaceutical development company.

The core allegation is simple to state and serious in effect. According to the charging documents, the defendants made it appear that human subjects had taken study medications and undergone the required testing when they had not. The government claims they used identification documents from people who never participated to manufacture fake records and test results, then caused that false data to flow into the clinical trial databases used to evaluate whether new drugs are safe and effective.

Every defendant is charged with conspiracy to commit wire fraud. Three of them also face three counts each of substantive wire fraud. The statutory maximum is 20 years per count. The detail that should catch every defense lawyer's eye is the fourth person, charged not by indictment but by criminal information. That structure almost always signals a plea and cooperation. Someone is talking.

This case follows the same pattern the government has used in every prior FDA criminal investigation of a South Florida research site: quiet record-gathering, an internal cooperator, and a multi-count indictment.

The criminal information filed against one staff member is the tell. That charging vehicle almost always signals a cooperation agreement already in place. The government builds these cases from the inside out.

What the Government Is Actually Building

This was not a regulatory dispute that escalated by accident. The FDA's Office of Criminal Investigations Miami Field Office ran the case, and the Justice Department's Health and Safety Unit inside the Criminal Division is prosecuting it. That pairing tells you the government treated this as a criminal matter from early on, not a paperwork problem to be resolved with a warning letter.

Clinical trial fraud cases are built from records the site itself generates. Sponsor payment records show what the site was paid and for which visits. Trial database submissions and electronic case report forms create a digital trail of every entry. Source documents, lab results, FDA Form 1572, and informed consent files can be compared against pharmacy logs, drug accountability records, and the actual whereabouts of the supposed subjects. When an FDA inspection turns up source records that do not match the data submitted to the sponsor, the matter can move from the inspection side of FDA to its criminal investigators.

The government does not need a confession. It builds these cases on documents and on insiders. A coordinator who entered fabricated data or a subject who was never in the building can become the cooperating witness whose account ties the paper trail to intent.

Exposure and Charges

The charging vehicle in these cases is wire fraud. Conspiracy to commit wire fraud is charged under 18 U.S.C. § 1349, and substantive wire fraud under 18 U.S.C. § 1343. Each carries a 20-year statutory maximum. Because trial conduct generates many electronic transmissions, the government can and does charge multiple substantive counts, which is why a single research site can produce an indictment with exposure measured in decades on paper.

Related statutes often ride alongside the fraud counts. False statements to a federal agency under 18 U.S.C. § 1001 and prohibited acts under the Food, Drug, and Cosmetic Act at 21 U.S.C. § 331 can apply when fabricated records reach the FDA. Aggravated identity theft is a live risk when real people's identification documents are used to create fake subjects, because that count carries a mandatory consecutive term.

The statutory maximum is not the real story at sentencing. Under the federal guidelines, the driver is loss, usually measured by the sponsor payments tied to the fraudulent work, and then enhancements for sophisticated means, the number of victims, and the defendant's role. A principal investigator who led the site faces a leadership enhancement; a coordinator who followed instructions has a different posture. Even modest sponsor payments can land in multi-year guideline ranges once the enhancements stack.

Wire fraud is the vehicle. But the guideline calculation drives the sentence. Loss amount, sophistication enhancement, victim count, and role in the offense stack quickly — often into multi-year ranges even on the first offense.

This Is Not the First South Florida Research Site to Be Charged

South Florida has become the center of gravity for clinical trial fraud enforcement, and the prior cases show where this one is headed. In the Tellus Clinical Research prosecution out of Miami, the principal investigator received 60 months in federal prison, the clinic owner received 71 months, another defendant received 46 months and a $2 million restitution order, and study coordinators drew 30-month sentences. In the Unlimited Medical Research case, a site director and study coordinator was sentenced to 30 months. Owners of AMB Research Center in Miami pleaded guilty to wire fraud conspiracy for falsifying asthma drug study data, and owners of A&R Research Group admitted to enrolling unqualified participants and fabricating spirometry and echocardiogram readings.

The throughline is that the FDA's Miami criminal office and the Health and Safety Unit have run this play before and know how to prove it. For anyone connected to a site under scrutiny, the question is not whether the government can build a clinical trial fraud case in this district. It plainly can. The question is what you do about it now.

Critical Mistakes People Make Early

The most damaging errors in these matters happen before anyone is charged, often in the first 48 hours of contact. Talking to FDA OCI agents without counsel is at the top of the list. These are armed federal criminal investigators, not the FDA inspectors a research site is used to seeing, and a friendly doorstep conversation becomes the government's best evidence of intent.

Producing source documents, emails, or database exports in response to a subpoena without a strategy is the second mistake. So is assuming a routine FDA inspection is purely regulatory when criminal investigators are already involved. Coordinators make a particular error in thinking they are too junior to be charged. The prior cases prove otherwise. The coordinators went to prison too. The final and most common mistake is waiting for an indictment to hire a federal criminal defense attorney. By then the cooperator slots are filled and the loss number is set.

If you receive a target letter or a grand jury subpoena connected to a research site, the right response is a target letter response handled through counsel, not a voluntary interview with the investigators.

"The most damaging errors happen before anyone is charged. Talking to OCI agents without counsel. Producing records without a strategy. Waiting for an indictment to hire a defense attorney. By then the cooperator slots are filled."— Aaron M. Cohen, AMC Defense Law

The Strategic Defense Approach

Clinical trial fraud cases are decided in the pre-indictment window. Early intervention lets counsel get in front of the loss calculation, which is the single most important number in the case, before the government locks it in. It also creates room to draw the line that matters most: the line between a genuine intent to defraud and the protocol deviations, documentation gaps, and sloppy practices that exist at many legitimate research sites. Not every charting error is fraud, and the government's theory should be tested against that distinction.

A federal healthcare fraud defense attorney with experience in clinical trial cases understands both the FDA regulatory framework and the federal criminal statutes the government uses. That combination matters when you are dealing with charging documents that blend regulatory violations with wire fraud conspiracy theories.

The cooperation versus litigation decision has to be made with clear eyes and made early. The criminal information filed against one staff member in this case is a reminder that the government rewards the people who come in first. That does not mean cooperation is right for everyone. It means the calculus is real and time-sensitive, and it should be evaluated by a white-collar defense attorney who has handled federal investigation defense in this exact posture. Where charges proceed, the work shifts to controlling the loss figure, positioning role and mitigation, and building the sentencing record long before sentencing day.

Why Timing Matters Right Now

Charging decisions in an investigation like this stay fluid until they are not. Prosecutors are deciding who is a target, who is a subject, and who gets the chance to resolve early, and those decisions harden over weeks. The person who retains counsel and opens a controlled dialogue with the government has options that disappear once the grand jury returns the indictment.

If you have received a target letter, a grand jury subpoena, or a visit from FDA criminal investigators connected to a research site, the window to influence the outcome is open now and closing. What you do in the next few weeks will shape the rest of the case.

Common Questions

Facing an FDA Investigation or Grand Jury Subpoena in Florida?

AMC Defense Law represents principal investigators, research site owners, study coordinators, and other professionals in federal investigations and prosecutions involving clinical trial fraud, healthcare fraud, and FDA enforcement, in Florida and nationwide. If you have been contacted by FDA criminal investigators, received a target letter or subpoena, or believe your research site is under review, the most valuable thing you have is time.

Pre-indictment defense lets AMC Defense Law get in front of the loss calculation, draw the line between fraud and protocol deviation, and shape the charging decision before it hardens.

If you or a family member is facing a federal investigation involving a research site or clinical trial fraud in Florida, call Aaron M. Cohen for a confidential consultation. 24 hours a day.

This article is provided for general informational purposes only and does not constitute legal advice. Reading it does not create an attorney-client relationship. The charges described are allegations only, and all defendants are presumed innocent unless and until proven guilty beyond a reasonable doubt. Every case is different. If you are facing a criminal investigation or charges, consult a qualified attorney about your specific situation.

About the author: Aaron M. Cohen is the founder of AMC Defense Law, a federal and state criminal defense firm based in Florida. The firm represents clients in federal investigations and prosecutions involving healthcare fraud, FDA and clinical research enforcement, white-collar crime, and complex federal litigation, in Florida and nationwide.